According to filings with the U.S. Securities and Exchange Commission, CSA Medical dba RejuvenAir is raising up to $11,217,710.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About CSA Medical dba RejuvenAir
CSA Medical dba RejuvenAir is a medical technology company focused on advancing spray cryotherapy for the treatment of Chronic Bronchitis, a major subset of COPD that affects millions of people. Its flagship product, the RejuvenAir System, is a revolutionary cryosurgical device that delivers a precise metered cryospray of -196C liquid nitrogen to targeted areas in the lungs via a minimally invasive bronchoscopic procedure, often performed on an outpatient or same-day basis. The system is designed to flash-freeze and destroy diseased airway surface cells while preserving the underlying extracellular structure, enabling the regrowth of healthy, normal-functioning cells such as cilia and mucus-producing goblet cells, and thereby addressing the underlying causes of chronic cough and dysfunctional mucus production rather than just symptoms. CSA Medical positions RejuvenAir as a unique, investigational therapy, noting that no current drug or device on the market directly targets the root cause of COPD with Chronic Bronchitis in this way, and the RejuvenAir System is already approved in the EU while remaining under clinical investigation in the United States. Through ongoing clinical studies and continued development of its proprietary liquid nitrogen spray cryotechnology and specialized delivery catheters, CSA Medical is committed to improving quality of life for patients suffering from COPD with Chronic Bronchitis.

To learn more, visit https://www.rejuvenair.com/
LinkedIn: https://www.linkedin.com/company/csa-medical-inc

Contact:
Wendelin Maners, President

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.